{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:29:03Z","timestamp":1777908543988,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    To evaluate the impact of comorbidities on treatment allocation and prognosis in anaplastic thyroid cancer, 137 patients from 10 German tertiary cancer centers treated with radiotherapy between 2001 and 2020 were analyzed. Four validated comorbidity scores were applied to assess comorbidity burden. The primary objective was to identify prognostic factors for the survival rate at 6 months after radiotherapy and discriminate the comorbidity scores using concordance statistics, ROC curve net reclassification index, and integrated discrimination improvement for 6-month survival. The median overall survival (OS) of the entire cohort was 4 months (95% CI\u2009=\u20092.72\u20135.28). The 6-, 12- and 24-months survival rates were 42.1%, 29.0% and 15.0%, respectively. In the univariate analysis, Karnofsky Performance Score (KPS) (&gt;\u200970%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), UICC stage (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), treatment modality (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), intention of treatment (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) as well as lower scores in the conventional Charlson Comorbidity Index (cCCI,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), the updated Charlson Comorbidity Index (uCCI,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) were associated with improved OS. KPS (&gt;\u200970%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.06) and type of therapy (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.087) showed a trend in multivariate analysis. Higher comorbidity burden (cCCI and uCCI) was associated with less intensive treatment and lower cumulative radiation doses in univariable analyses. However, after adjustment for age and metastatic status, none of the comorbidity indices remained independently associated with the use of multimodal therapy or the prescribed EQD2 dose (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.05). Age, but not metastatic status, was linked to a reduced likelihood of receiving multimodal treatment. In contrast, KPS emerged as the only independent predictor of higher EQD2 dose levels in the multivariable models.\n                  <\/jats:p>","DOI":"10.1007\/s00432-025-06403-7","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:39:06Z","timestamp":1766511546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of comorbidities on treatment management and prognosis in patients with anaplastic thyroid cancer (ATC)"],"prefix":"10.1007","volume":"152","author":[{"given":"Teresa","family":"Augustin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmytro","family":"Oliinyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlen","family":"Haderlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Frei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Medenwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike","family":"Trommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"M\u00e4urer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Drozdz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"R\u00fchle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca-Ligia","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils Henrik","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Waltenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie E.","family":"Combs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastassia","family":"L\u00f6ser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Theodor","family":"Eich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefine","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Gurtner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Renollet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Spitzweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Vordermark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"K\u00e4smann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"6403_CR1","doi-asserted-by":"publisher","first-page":"000","DOI":"10.1097\/COC.0000000000001246","volume":"00","author":"B Alhayek","year":"2025","unstructured":"Alhayek B, Baidoun F, Hadidi D, Alhaj Moustafa M, Abdel-Rahman O (2025) Impact of intensive multimodal treatment on the outcomes of patients with anaplastic thyroid cancer. Am J Clin Oncol. https:\/\/doi.org\/10.1097\/COC.0000000000001246","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"6403_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1200\/JCO.2007.12.8322","volume":"26","author":"TR Asmis","year":"2008","unstructured":"AsmisTR, Ding K, Seymour L et al (2008) Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada clinical trials group trials. J Clin Oncol 26(1):54\u201359. https:\/\/doi.org\/10.1200\/JCO.2007.12.8322","journal-title":"J Clin Oncol"},{"issue":"10","key":"6403_CR3","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.3390\/jcm9103231","volume":"9","author":"T Augustin","year":"2020","unstructured":"Augustin T, Oliinyk D, Koehler VF et al (2020) Clinical outcome and toxicity in the treatment of anaplastic thyroid cancer in elderly patients. J Clin Med 9(10):3231. https:\/\/doi.org\/10.3390\/jcm9103231","journal-title":"J Clin Med"},{"key":"6403_CR4","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0944","author":"KC Bible","year":"2021","unstructured":"Bible KC, Kebebew E, Brierley J et al (2021) 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. https:\/\/doi.org\/10.1089\/thy.2020.0944","journal-title":"Thyroid"},{"issue":"5","key":"6403_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"issue":"11","key":"6403_CR5","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J et al (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245\u20131251. https:\/\/doi.org\/10.1016\/0895-4356(94)90129-5","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"6403_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","volume":"91","author":"ME Charlson","year":"2022","unstructured":"Charlson ME, Carrozzino D, Guidi J et al (2022) Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom 91(1):8\u201335. https:\/\/doi.org\/10.1159\/000521288","journal-title":"Psychother Psychosom"},{"issue":"10","key":"6403_CR8","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/sj.bjc.6602836","volume":"93","author":"B Colinet","year":"2005","unstructured":"Colinet B, Jacot W, Bertrand D et al (2005) A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the charlson\u2019s index. Br J Cancer 93(10):1098\u20131105. https:\/\/doi.org\/10.1038\/sj.bjc.6602836","journal-title":"Br J Cancer"},{"key":"6403_CR9","doi-asserted-by":"publisher","first-page":"8218949","DOI":"10.1155\/2019\/8218949","volume":"2019","author":"KL Corrigan","year":"2019","unstructured":"Corrigan KL, Williamson H, Elliott Range D et al (2019) Treatment outcomes in anaplastic thyroid cancer. J Thyroid Res 2019:8218949 https:\/\/doi.org\/10.1155\/2019\/8218949","journal-title":"J Thyroid Res"},{"issue":"6","key":"6403_CR11","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613\u2013619. https:\/\/doi.org\/10.1016\/0895-4356(92)90133-8","journal-title":"J Clin Epidemiol"},{"key":"6403_CR10","doi-asserted-by":"publisher","first-page":"S1295","DOI":"10.1016\/j.annonc.2022.07.1726","volume":"33","author":"C Dierks","year":"2022","unstructured":"Dierks C, Ruf J, Seufert J et al (2022) 1646MO phase II ATLEP trial: final results for lenvatinib\/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma. Ann Oncol 33:S1295. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1726","journal-title":"Ann Oncol"},{"issue":"9","key":"6403_CR12","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/cncr.28509","volume":"120","author":"BK Edwards","year":"2014","unstructured":"EdwardsBK, Noone A-M, Mariotto AB et al (2014) Annual report to the Nation on the status of cancer, 1975\u20132010, featuring prevalence of comorbidity and impact on survival among persons with Lung, Colorectal, breast or prostate cancer. Cancer 120(9):1290\u20131314 https:\/\/doi.org\/10.1002\/cncr.28509","journal-title":"Cancer"},{"issue":"2","key":"6403_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/cncr.32548","volume":"126","author":"D Fan","year":"2019","unstructured":"Fan D, Ma J, Bell AC et al (2019) Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. Cancer 126(2):444\u2013452","journal-title":"Cancer"},{"issue":"12","key":"6403_CR14","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","volume":"30","author":"S Filetti","year":"2019","unstructured":"Filetti S, Durante C, Hartl D et al (2019) Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(12):1856\u20131883. https:\/\/doi.org\/10.1093\/annonc\/mdz400","journal-title":"Ann Oncol"},{"issue":"S1","key":"6403_CR15","doi-asserted-by":"publisher","first-page":"E2083","DOI":"10.1002\/hed.24384","volume":"38","author":"SM Glaser","year":"2016","unstructured":"Glaser SM, Mandish SF, Gill BS et al (2016) Anaplastic thyroid cancer: prognostic factors, patterns of care, and overall survival. Head Neck 38(S1):E2083\u2013E2090","journal-title":"Head Neck"},{"issue":"11","key":"6403_CR16","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1002\/cam4.882","volume":"5","author":"I G\u00f6llnitz","year":"2016","unstructured":"G\u00f6llnitz I, Inhestern J, Wendt TG et al (2016) Role of comorbidity on outcome of head and neck cancer: a population-based study in Thuringia, Germany. Cancer Med 5(11):3260\u20133271. https:\/\/doi.org\/10.1002\/cam4.882","journal-title":"Cancer Med"},{"key":"6403_CR17","doi-asserted-by":"publisher","first-page":"e9173","DOI":"10.7717\/peerj.9173","volume":"8","author":"W Gui","year":"2020","unstructured":"Gui W, Zhu W, Lu W et al (2020) Development and validation of a prognostic nomogram to predict overall survival and cancer-specific survival for patients with anaplastic thyroid carcinoma. PeerJ 8:e9173. https:\/\/doi.org\/10.7717\/peerj.9173","journal-title":"PeerJ"},{"issue":"8","key":"6403_CR18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","volume":"20","author":"RI Haddad","year":"2022","unstructured":"Haddad RI, Bischoff L, Ball D et al (2022) Thyroid Carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(8):925\u2013951. https:\/\/doi.org\/10.6004\/jnccn.2022.0040","journal-title":"J Natl Compr Canc Netw"},{"issue":"17","key":"6403_CR19","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1002\/cncr.28187","volume":"119","author":"MR Haymart","year":"2013","unstructured":"Haymart MR, Banerjee M, Yin H et al (2013) Marginal treatment benefit in anaplastic thyroid cancer. Cancer 119(17):3133\u20133139. https:\/\/doi.org\/10.1002\/cncr.28187","journal-title":"Cancer"},{"issue":"2","key":"6403_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00408-016-9857-4","volume":"194","author":"L Kaesmann","year":"2016","unstructured":"Kaesmann L, Janssen S, Schild SE et al (2016) Value of comorbidity scales for predicting survival after radiochemotherapy of small cell lung cancer. Lung 194(2):295\u2013298. https:\/\/doi.org\/10.1007\/s00408-016-9857-4","journal-title":"Lung"},{"issue":"25","key":"6403_CR21","doi-asserted-by":"publisher","first-page":"e11037","DOI":"10.1097\/MD.0000000000011037","volume":"97","author":"J-H Lee","year":"2018","unstructured":"LeeJ-H, Ahn HK, Seok JY et al (2018) Optimal combination of treatment modality to increase survival in patients with anaplastic thyroid carcinoma. Medicine 97(25):e11037 https:\/\/doi.org\/10.1097\/MD.0000000000011037","journal-title":"Medicine"},{"key":"6403_CR22","doi-asserted-by":"publisher","first-page":"11435","DOI":"10.1038\/s41598-019-47898-8","volume":"9","author":"YK Lee","year":"2019","unstructured":"Lee YK, Hong N, Park SH et al (2019) The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma. Sci Rep 9:11435. https:\/\/doi.org\/10.1038\/s41598-019-47898-8","journal-title":"Sci Rep"},{"issue":"2","key":"6403_CR23","doi-asserted-by":"publisher","first-page":"949","DOI":"10.21873\/anticanres.13198","volume":"39","author":"M Li","year":"2019","unstructured":"Li M, Gu S, Mao R et al (2019) County median family income is an independent prognostic factor for stage IV anaplastic thyroid cancer. Anticancer Res 39(2):949\u2013956","journal-title":"Anticancer Res"},{"issue":"9","key":"6403_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"Maniakas A, Dadu R, Busaidy NL et al (2020) Evaluation of overall survival in patients with anaplastic thyroid Carcinoma, 2000\u20132019. JAMA Oncol 6(9):1\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3362","journal-title":"JAMA Oncol"},{"issue":"3","key":"6403_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3390\/cancers12030552","volume":"12","author":"N Onoda","year":"2020","unstructured":"Onoda N, Sugitani I, Ito K et al (2020) Evaluation of the 8th edition TNM classification for anaplastic thyroid carcinoma. Cancers 12(3):552. https:\/\/doi.org\/10.3390\/cancers12030552","journal-title":"Cancers"},{"issue":"8","key":"6403_CR26","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.gassur.2004.09.045","volume":"8","author":"JR Ouellette","year":"2004","unstructured":"Ouellette JR, Small DG, Termuhlen PM (2004) Evaluation of Charlson-Age comorbidity index as predictor of morbidity and mortality in patients with colorectal carcinoma. J Gastrointest Surg 8(8):1061\u20131067. https:\/\/doi.org\/10.1016\/j.gassur.2004.09.045","journal-title":"J Gastrointest Surg"},{"issue":"9","key":"6403_CR27","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/cncr.30493","volume":"123","author":"TA Pezzi","year":"2017","unstructured":"Pezzi TA, Mohamed ASR, Sheu T et al (2017) Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the National cancer data base. Cancer 123(9):1653\u20131661. https:\/\/doi.org\/10.1002\/cncr.30493","journal-title":"Cancer"},{"issue":"20","key":"6403_CR28","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","volume":"291","author":"JF Piccirillo","year":"2004","unstructured":"Piccirillo JF, Tierney RM, Costas I et al (2004) Prognostic importance of comorbidity in a Hospital-Based cancer registry. JAMA 291(20):2441\u20132447. https:\/\/doi.org\/10.1001\/jama.291.20.2441","journal-title":"JAMA"},{"issue":"12","key":"6403_CR29","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1210\/jc.2017-01180","volume":"102","author":"N Prasongsook","year":"2017","unstructured":"Prasongsook N, Kumar A, Chintakuntlawar AV et al (2017) Survival in response to multimodal therapy in anaplastic thyroid cancer. J Clin Endocrinol Metab 102(12):4506\u20134514. https:\/\/doi.org\/10.1210\/jc.2017-01180","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6403_CR30","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00423-002-0291-0","volume":"387","author":"R Rieker","year":"2002","unstructured":"Rieker R, Hammer E, Eisele R et al (2002) The impact of comorbidity on the overall survival and the cause of death in patients after colorectal cancer resection. Langenbeck\u2019s Arch Surg 387(2):72\u201376. https:\/\/doi.org\/10.1007\/s00423-002-0291-0","journal-title":"Langenbeck\u2019s Arch Surg"},{"issue":"3","key":"6403_CR31","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ygyno.2013.10.007","volume":"131","author":"JR Robbins","year":"2013","unstructured":"Robbins JR, Gayar OH, Zaki M et al (2013) Impact of age-adjusted Charlson comorbidity score on outcomes for patients with early-stage endometrial cancer. Gynecol Oncol 131(3):593\u2013597. https:\/\/doi.org\/10.1016\/j.ygyno.2013.10.007","journal-title":"Gynecol Oncol"},{"issue":"1","key":"6403_CR32","doi-asserted-by":"publisher","first-page":"e67759","DOI":"10.5812\/ijem.67759","volume":"17","author":"B Salehian","year":"2019","unstructured":"SalehianB, Liem SY, Mojazi Amiri H et al (2019) Clinical trials in management of anaplastic thyroid Carcinoma; progressions and set backs: A systematic review. Int J Endocrinol Metab 17(1):e67759 https:\/\/doi.org\/10.5812\/ijem.67759","journal-title":"Int J Endocrinol Metab"},{"issue":"4","key":"6403_CR33","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1245\/s10434-006-9296-1","volume":"14","author":"A Sanabria","year":"2007","unstructured":"Sanabria A, Carvalho AL, Vartanian JG et al (2007) Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 14(4):1449\u20131457. https:\/\/doi.org\/10.1245\/s10434-006-9296-1","journal-title":"Ann Surg Oncol"},{"issue":"sup1","key":"6403_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2147\/CLEP.S47150","volume":"5","author":"M S\u00f8gaard","year":"2013","unstructured":"S\u00f8gaard M, Thomsen RW, Bossen KS et al (2013) The impact of comorbidity on cancer survival: a review. Clin Epidemiol 5(sup1):3\u201329. https:\/\/doi.org\/10.2147\/CLEP.S47150","journal-title":"Clin Epidemiol"},{"issue":"1","key":"6403_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA et al (2018) Dabrafenib and Trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013Mutant anaplastic thyroid cancer. J Clin Oncol 36(1):7\u201313. https:\/\/doi.org\/10.1200\/JCO.2017.73.6785","journal-title":"J Clin Oncol"},{"issue":"1","key":"6403_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1272\/jnms.2018_85-3","volume":"85","author":"I Sugitani","year":"2018","unstructured":"Sugitani I, Onoda N, Ito K et al (2018) Management of anaplastic thyroid carcinoma: the fruits from the ATC research consortium of Japan. J Nippon Med Sch 85(1):18\u201327. https:\/\/doi.org\/10.1272\/jnms.2018_85-3","journal-title":"J Nippon Med Sch"},{"issue":"11","key":"6403_CR37","doi-asserted-by":"publisher","first-page":"e80011","DOI":"10.1371\/journal.pone.0080011","volume":"8","author":"C Sun","year":"2013","unstructured":"SunC, Li Q, Hu Z et al (2013) Treatment and prognosis of anaplastic thyroid carcinoma: experience from a single institution in China. PLoS ONE 8(11):e80011 https:\/\/doi.org\/10.1371\/journal.pone.0080011","journal-title":"PLoS ONE"},{"issue":"5","key":"6403_CR38","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/hed.23947","volume":"38","author":"JR Wang","year":"2016","unstructured":"Wang JR, Habbous S, Espin\u2013Garcia O et al (2016) Comorbidity and performance status as independent prognostic factors in patients with head and neck squamous cell carcinoma. Head Neck 38(5):736\u2013742. https:\/\/doi.org\/10.1002\/hed.23947","journal-title":"Head Neck"},{"key":"6403_CR39","doi-asserted-by":"publisher","first-page":"e2100504","DOI":"10.1200\/PO.21.00504","volume":"6","author":"JR Wang","year":"2022","unstructured":"Wang JR, Montierth M, Xu L et al (2022) Impact of somatic mutations on survival outcomes in patients with anaplastic thyroid carcinoma. JCO Precis Oncol 6:e2100504. https:\/\/doi.org\/10.1200\/PO.21.00504","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"6403_CR40","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1530\/EJE-16-0574","volume":"175","author":"J Wendler","year":"2016","unstructured":"Wendler J, Kroiss M, Gast K et al (2016) Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. Eur J Endocrinol 175(6):521\u2013529. https:\/\/doi.org\/10.1530\/EJE-16-0574","journal-title":"Eur J Endocrinol"},{"key":"6403_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2017.05.024","volume":"81","author":"T Yamano","year":"2017","unstructured":"Yamano T, Yamauchi S, Kimura K et al (2017) Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: a retrospective multicentre study. Eur J Cancer 81:90\u2013101. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.024","journal-title":"Eur J Cancer"},{"issue":"7","key":"6403_CR42","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1273::AID-CNCR13>3.0.CO;2-4","volume":"80","author":"R Yancik","year":"1997","unstructured":"Yancik R (1997) Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 80(7):1273\u20131283","journal-title":"Cancer"},{"issue":"4","key":"6403_CR43","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1089\/thy.2022.0504","volume":"33","author":"X Zhao","year":"2023","unstructured":"Zhao X, Wang JR, Dadu R et al (2023) Surgery after BRAF-Directed therapy is associated with improved survival in BRAFV600E mutant anaplastic thyroid cancer: a single-center retrospective cohort study. Thyroid 33(4):484\u2013491. https:\/\/doi.org\/10.1089\/thy.2022.0504","journal-title":"Thyroid"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06403-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06403-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06403-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:39:07Z","timestamp":1766511547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06403-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6403"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06403-7","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Teresa Augustin: No conflicts of interest to disclose; Dmytro Oliinyk: No conflicts of interest to disclose; Marlen Haderlein: No conflicts of interest to disclose; Charlotte Frei: No conflicts of interest to disclose; Julia Jacob: No conflicts of interest to disclose; Daniel Medenwald: No conflicts of interest to disclose; Maike Trommer: No conflicts of interest to disclose; Matthias M\u00e4urer: No conflicts of interest to disclose; Sonia Drozdz: No conflicts of interest to disclose; Alexander Ruehle: No conflicts of interest to disclose; Anca Grosu: No conflicts of interest to disclose; Nils Henrik Nicolay: No conflicts of interest to disclose; Maria Waltenberger: No conflicts of interest to disclose; Stephanie E. Combs: No conflicts of interest to disclose; Anastassia L\u00f6ser: No conflicts of interest to disclose; Michael Oertel: No conflicts of interest to disclose; Hans Theodor Eich: No conflicts of interest to disclose; Stefan Janssen: No conflicts of interest to disclose; Josefine Rauch: No conflicts of interest to disclose; Ralph Gurtner: No conflicts of interest to disclose; Robert Renollet: No conflicts of interest to disclose; Christine Spitzweg: No conflicts of interest to disclose; Dirk Vordermark: No conflicts of interest to disclose; Claus Belka: No conflicts of interest to disclose; Lukas K\u00e4smann: No conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"22"}}